The risk to benefit profile of these agents and outcomes data are key as we evaluate the evidence
These trials have enriched the therapeutic landscape for T2D patients, offering a range of GLP-1 receptor agonists with varying cardiovascular profiles, thus allowing clinicians to personalize treatment for each patient
Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Among Indian companies, Dr
Moreover, there are a few studies which indicate that these compounds may also prove useful in the treatment of neuropsychiatric disorders including depression [19, 20]
But if it were that great, wouldnt organizations like the American Diabetes Association be loudly endorsing GLP-1 microdosing